جستجوی استاد راهنمای دانشگاهی

• Lymphoma
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• +۵ مورد دیگر

Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.

Mark R. Pittelkowمشاهده پروفایل

استاد

• Dermatology
• Cutaneous Lymphomas
• Photoprotection
• +۳ مورد دیگر

Mark R. Pittelkow is a Professor of Dermatology at the Mayo Clinic, holding a primary appointment as a Consultant in the Department of Dermatology. He completed his MD at Mayo Medical School and advanced training through Mayo Graduate School of Medicine and Northwestern University. His research focuses on cutaneous lymphomas, photoprotection, and skin cancer, with leadership roles in international guidelines (ISCL/EORTC). He contributes to clinical trials, medical education, and interdisciplinary research through affiliations like the Mayo Clinic Comprehensive Cancer Center and Regenerative Biotherapeutics. Education: MD (Mayo Medical School), MS (Biological Sciences, Northwestern), BA (Northwestern University). Research spans cutaneous lymphoma classification, immunology, and translational dermatology. Notable publications address staging systems for mycosis fungoides/Sezary syndrome and photoprotection strategies. His work integrates clinical practice with molecular mechanisms, such as JAK inhibitor responses in lichen planus. Labs/Teams: Collaborates with Mayo Clinic Cancer Center and interdisciplinary groups in immunotherapy and regenerative medicine. Supervises clinical trials and postdoctoral training programs.

Fnu Aakashمشاهده پروفایل

استادیار

• Hematopathology
• Oncology
• Cancer Diagnostics
• +۲ مورد دیگر

Dr. Fnu Aakash serves as Interim Director of Hematopathology and Assistant Professor in the Department of Pathology at the University of Texas Medical Branch. His research focuses on hematopathology, oncology diagnostics, and clinical significance of neoplastic disorders. With an h-index of 55, Aakash has contributed significantly to cancer classification systems through publications in Modern Pathology and American Journal of Surgical Pathology. His recent work includes developing international consensus guidelines for myelodysplastic neoplasms and characterizing non-neoplastic changes associated with breast implants. Research collaborations span multiple institutions including MD Anderson Cancer Center, with specialization in malignant hematology and lymphoma diagnostics.

Andrew L. Feldmanمشاهده پروفایل

استاد

• Molecular Pathogenesis
• T-cell Lymphoma
• Lymphoma Genetics
• +۵ مورد دیگر

Andrew L. Feldman, MD , is a Professor of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, Minnesota. He specializes in the molecular pathogenesis of T-cell lymphomas, focusing on genetic abnormalities, biomarkers, and individualized therapies. His work bridges next-generation sequencing (NGS) infrastructure and translational research to improve lymphoma diagnosis and subclassification. Primary Appointment: Consultant, Division of Hematopathology Joint Appointment: Consultant, Division of Experimental Pathology and Laboratory Medicine Education: MD, Brown University (1991) BA, Brown University (1986) Clinical Fellowship, Hematopathology, National Cancer Institute (2006) Research Interests: Dr. Feldman's research explores the genetic basis of T-cell lymphomas, which are often fatal. By characterizing mutations (e.g., DUSP22 , TP63 , STAT3 ) and applying bioinformatics, his team develops diagnostic tests to predict therapeutic responses. He also investigates how genetic heterogeneity impacts lymphoma classification and treatment strategies. Scientific Awards: Berard-Dorfman Founders Award, Society for Hematopathology (2015) Recipient Medal, Pedro Ruiz Gallo National University, Peru (2007) Artemis Fellowship, Nikolas Symposium XV, Athens (2005) NIH Fellows Award for Research Excellence (2003, 2000) First Prize, Resident Paper Competition (1999) Daland Award, New England Cancer Society (1999) Outstanding Junior Resident Teaching Award (1996) Joseph Collins Foundation Scholarship (1988) Advising and Grants: Dr. Feldman has directed the Mayo Clinic Biospecimens Core and led NCI-funded projects like the Lymphoma Specialized Program of Research Excellence (SPORE) and Molecular Classification of Anaplastic Large Cell Lymphoma . He has served on NCI Lymphoma Steering Committee and Mayo Clinic's NGS Infrastructure Subcommittee. Laboratory and Collaborations: His lab collaborates with the International Lymphoma Study Group , Mayo Clinic Comprehensive Cancer Center , and Association for Molecular Pathology . He co-developed clinical trials linking molecular profiling to therapeutic targets and contributed to the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) Research Consortium.

Jeremy Wangمشاهده پروفایل

استادیار

• Computational Biology
• Genomics
• Microbiome Research
• +۷ مورد دیگر

Jeremy Wang, PhD is an Assistant Professor in the Department of Genetics at the UNC School of Medicine . His research focuses on applying high-performance computational methods and machine learning to analyze high-throughput sequence data using long-read technologies (e.g., Oxford Nanopore) to advance precision personalized medicine . Key disease areas include Inflammatory Bowel Diseases (IBD) Respiratory Infectious Diseases His lab specializes in microbiome analysis , host-pathogen interactions , and computational genomics , working with collaborators in clinical, translational, and computational domains. His publications demonstrate expertise in long-read sequencing applications for Pediatric cancer classification SARS-CoV-2 genomic epidemiology Microbiome spatiotemporal dynamics Murine disease models Drosophilid genome assemblies Metagenomic bias analysis Collaborations span UNC and global institutions, with current work extending to clinical laboratory partnerships for pathogen sequencing and oral microbiome sampling methodology.

• Cancer Genomics
• Liquid Biopsies
• Machine Learning in Oncology
• +۷ مورد دیگر

Ash A. Alizadeh is the Moghadam Family Professor of Medicine, Oncology, and Hematology (by courtesy) at Stanford University, where he serves as leader of the Cancer Genomics Program at Stanford Cancer Institute. He holds multiple academic appointments including Professor in Medicine - Oncology, and membership in Bio-X, the Institute for Stem Cell Biology and Regenerative Medicine, and the Maternal & Child Health Research Institute (MCHRI). Dr. Alizadeh received his BS in Biochemistry from UCLA (1994), MD from Stanford Medical School, and PhD in Biophysics from Stanford. He completed additional training at the National Cancer Institute (NCI), the National Institutes of Health (NIH), and the Howard Hughes Medical Institute (HHMI). His primary research focuses on developing and applying genome technologies and computing (machine learning & data science) to problems in human disease, with special emphasis on cancer detection, classification, monitoring, and tumor immunology. His laboratory pioneers noninvasive cancer genomic techniques including CAPP-Seq, PhasED-Seq, and EPIC-Seq for "liquid biopsies" that analyze circulating nucleic acids for early cancer detection and monitoring therapeutic response. Using machine learning approaches, his group studies how cellular compositional variation impacts cancer behavior and therapeutic response, including anti-tumor immunity. His work spans molecular, cellular, organism and population levels of tumor behavior analysis. Dr. Alizadeh has received numerous prestigious awards including the Scholar Award from the American Society of Hematology (ASH), the Leukemia & Lymphoma Society (LLS), the V-Foundation, as well as awards from the American Red Cross, Damon Runyon Cancer Research Foundation, and Doris Duke Charitable Research Foundation. He is an elected member of the American Society for Clinical Investigation (ASCI) and serves on the Scientific Advisory Board of the Lymphoma Research Foundation (LRF). As an educator and mentor, Dr. Alizadeh advises numerous doctoral students, postdoctoral fellows, and medical scholars. He teaches in the Department of Medicine and Immunology and serves on various admissions panels at Stanford. His laboratory, the Alizadeh Lab, is a hub for interdisciplinary cancer genomics research that combines computational biology, molecular genetics, and clinical oncology to develop novel cancer diagnostics and therapeutics.

• Artificial Intelligence in Healthcare
• Precision Medicine
• Machine Learning Applications in Healthcare
• +۵ مورد دیگر

Magnus Boman is a Professor of AI and Health at the Department of Medicine, Solna, Karolinska Institutet (KI), where he leads the AI@KI initiative to support researchers in AI integration. He is affiliated with the Chronic Inflammatory Disease Epidemiology research group under Johan Askling. His research focuses on AI applications in precision medicine, multimodal prediction, ethical norms in AI systems, energy-efficient computing, and quantum sensor data interpretation. Research Interests: Artificial Intelligence in healthcare and precision medicine Multimodal data analysis for disease prediction and treatment Machine learning for clinical decision support systems Ethical and societal implications of AI Grants: Swedish Research Council: Improving breast cancer histology image classification (2024-2026) Scalable Federated Learning (2022-2025) Ai in sustainable cities (VINNOVA, 2019) Advising & Students: Supervised over 50 PhD and Master's students across KI, KTH, and Stockholm University, focusing on AI applications in healthcare, machine learning, and computational epidemiology. Notable projects include predictive modeling for mental health outcomes and variant filtering in genetic data. Labs & Teams: Leads AI@KI, fostering AI adoption in medical research. Collaborates with the Johan Askling group on epidemiology and chronic disease studies.

Jude M. Phillipمشاهده پروفایل

استادیار

• Aging
• Mechanobiology
• Cancer Biology
• +۵ مورد دیگر

Jude M. Phillip, PhD, is an Assistant Professor in the Departments of Biomedical Engineering and Chemical and Biomolecular Engineering at Johns Hopkins University. His research integrates engineering principles with aging and cancer biology to develop cell-based biomarkers and mechanistic insights into age-related diseases. He leads the Phillip tiME Lab, which focuses on aging dynamics, tumor microenvironment interactions, and translational technologies. Education : PhD, Chemical and Biomolecular Engineering, Johns Hopkins University, 2015 Postdoctoral Research, Melnick/Cerchietti Labs, Weill Cornell Medicine, 2016-2020 B.Eng, Chemical Engineering, City College of New York, 2010 Research Interests : Dr. Phillip’s work spans aging mechanisms, cancer biology, and mechanobiology. Key areas include: Cell-based biomarkers for aging and disease Scale-dependent aging pathways Lymphoma tumor-immune microenvironment (tiME) Single-cell profiling of senescence subtypes ECM mechanoregulation of stem cell fate His lab employs longitudinal cell profiling, data science, and clinical measures to bridge biological aging research with translational medicine. Recent Highlights : 2025: NIH R35 MIRA Award for lymphoma microenvironment research 2024: Johns Hopkins Catalyst Award for aging biomarker studies 2023: AFAR-Glenn Foundation Award for senescence subtype classification Lab & Collaborations : The Phillip Lab collaborates with the Institute for NanoBioTechnology and maintains a living patient-derived tumor biorepository for lymphoma studies. Current projects include ovarian aging organoid models and immune-mechanical interactions in cancer progression.

Simon Crouchمشاهده پروفایل

پژوهشگر ارشد

• Statistical Modeling
• Epidemiology
• Cancer Research
• +۶ مورد دیگر

Simon Crouch is a Senior Research Fellow in Biostatistics at the University of York's Health Sciences department. With a strong mathematical background from Cambridge and Warwick, he leads the analytics team within the Epidemiology and Cancer Statistics Group and works closely with the Haematological Malignancy Research Network (HMRN) and Cardiovascular Health team. His work focuses on statistical modeling of complex epidemiological data related to hematological malignancies. University of Cambridge: MA, MMath in Mathematics University of Warwick: PhD in Mathematics University of Lancaster: MSc in Medical Statistics Dr. Crouch specializes in the statistical modeling of complex epidemiological data, with particular focus on hematological malignancies. His research encompasses predictive modeling, event history analysis, and machine learning applications in cancer epidemiology. He has made significant contributions to understanding myelodysplastic syndromes, lymphoma classification, and survival analysis in blood cancers through population-based studies. His work often involves collaboration with international registries including the European Myelodysplastic Syndromes Registry (EUMDS) and the Haematological Malignancy Research Network. Analysis of his recent publications reveals a strong focus on myelodysplastic syndromes (MDS), with particular attention to risk stratification, survival analysis, and treatment outcomes. His work increasingly incorporates genomic and molecular data to refine disease classification and prediction models. The trend shows progression from purely statistical methodology development toward integrated translational research that combines clinical, genomic, and epidemiological data to improve patient outcomes. Extensive publication record with 113 research outputs including 66 articles, 21 patents, and numerous meeting abstracts Active participation in major international research consortia including MDS-RIGHT and ImmunAID Significant contributions to the development of statistical methodologies for cancer epidemiology Dr. Crouch actively supervises PhD students in mathematical and statistical modeling applied to cancer epidemiology, with particular interest in time-to-event models, complex longitudinal models, and simulation techniques. His research has been supported through multiple projects, including the European Myelodysplastic Syndromes Registry and the MDS-RIGHT project focused on facilitating informed decision-making in hemato-oncology. He contributes to the Advanced Health and Social Statistics module for postgraduate students at the University of York.

Albert Koulmanمشاهده پروفایل

پژوهشگر

• Metabolomics
• Lipidomics
• Analytical Chemistry
• +۴ مورد دیگر

Dr. Albert Koulman is a Principal Research Associate at the University of Cambridge, affiliated with the Metabolic Research Laboratories (MRL) within the Institute of Metabolic Science. His work focuses on developing advanced analytical methods for metabolomics and lipidomics to understand metabolic processes in diseases. Department: Department of Clinical Biochemistry, University of Cambridge Key Roles: Scientific Director of the NIHR BRC Metabolomics and Lipidomics facility Research Interests 1. Metabolism in Pregnancy & Early Life: Collaborates with international teams to study lipid metabolism during pregnancy and infancy, developing biomarkers for gestational diabetes, infant nutrition, and childhood obesity risks. 2. Technological Innovations: Leads development of single-cell lipidomics and organelle-specific lipid profiling, establishing a full pipeline from sample preparation to bioinformatics. 3. Nutritional Biomarker Methodology: Specializes in dried blood spot applications for lipid analysis in clinical and population studies, supported by the MRC Epidemiology Unit. Article Trends Recent publications highlight his expertise in lipid metabolism across diseases (e.g., diabetes, melanoma, NAFLD). Key themes include sexual dimorphism in lipid biosynthesis, vitamin D dynamics during exercise, stromal lipid influences on cancer progression, and malnutrition recovery protocols. Methodological advancements (LC-MS/MS, single-cell analysis) and global health applications (Gambian maternal nutrition, pediatric rehabilitation) are recurring topics. Group Members & Collaborations Dr. Ben Jenkins (Analytical Chemist) Ms. Paulina Guevara Dominguez (Research Assistant) Ms. Nina van der Velde (MPhil Student) Collaborators: Sue Ozanne (Pregnancy Metabolism), MJFF (Parkinson’s research), MRC (Epidemiology Unit) Research Funding Biotechnology and Biological Sciences Research Council (BBSRC) JPI (Joint Programming Initiative) Michael J. Fox Foundation (MJFF) Medical Research Council (MRC) National Institute for Health and Care Research (NIHR)

• Neuroradiology
• Biomedical Informatics
• Head and Neck Imaging
• +۳ مورد دیگر

Dr. Richard H. Wiggins serves as Professor of Radiology and Imaging Sciences at the University of Utah School of Medicine, where he also holds the position of Associate Dean of Continuing Medical Education. He maintains adjunct professorships in Otolaryngology, Head and Neck Surgery, and Biomedical Informatics. His educational background includes a BA in Biochemistry from the University of Texas at Austin and an MD from the University of Texas at Houston Health Sciences Center, followed by specialized training at the University of Florida and University of Utah. Dr. Wiggins's research spans neuroradiology, biomedical informatics, and medical education innovation. His work explores advanced imaging techniques for head and neck pathologies, PET-CT applications in oncology, and the development of novel educational platforms like the RadDiscord community. He maintains particular expertise in temporal bone imaging, paragangliomas, and thyroid nodule classification systems. Analysis of his recent publications shows strong emphasis on: (1) optimizing oncologic imaging protocols, especially PET-CT applications across cancer types; (2) advancing head and neck radiology through volumetric analysis and radiomics; and (3) transforming radiology education via gamification and digital communities. His scientific honors include: Distinguished Teaching Award (Otolaryngology, University of Utah) Honored Educator Award (Radiological Society of North America) Inaugural Fellow, Academy of Health Science Educators 25th Fellow of the Society of Imaging Informatics in Medicine Fellow of the American College of Radiology He leads the Utah Head and Neck Imaging Center of Excellence, which includes an educational YouTube channel (@UHNICE). While specific grants aren't detailed, his extensive lecture record (600+ presentations) and leadership roles in professional societies like SIIM (Program Chair 2014-2020), ASHNR (Past President), and WNRS (Past President) demonstrate significant academic influence.

Ghazaleh Tabatabaiمشاهده پروفایل

استاد

• Neuro-Oncology
• Glioma Biology
• Meningioma Research
• +۵ مورد دیگر

Professor Ghazaleh Tabatabai serves as Head of Department for Clinical and Experimental Neuro-Oncology at the Hertie Institute for Clinical Brain Research, University of Tübingen. She leads a multidisciplinary research group focused on translational neuro-oncology with active collaborations through the German Glioma Network, German Cancer Consortium (DKTK), European Organisation for Research and Treatment of Cancer (EORTC), European Association of Neuro-Oncology (EANO), and International Consortium on Meningioma (ICOM). Her research program centers on molecular mechanisms of tumorigenesis, therapy resistance, and treatment-induced vulnerabilities in nervous system tumors. The laboratory employs CRISPR screening technologies, molecular profiling, and preclinical models to identify therapeutic targets, with particular expertise in glioma and meningioma biology. Current projects span from discovery through validation to clinical application, including phase I/II trials of novel therapies such as CureVac's mRNA vaccine candidate CVGBM. Recent publications demonstrate leadership in molecular classification of meningiomas, CRISPR-based target discovery, immunotherapy development, and clinical trial design. Her work on the TRACE app for patient-reported outcomes and the PRIDE trial for dose-escalated radiation therapy represents significant clinical translation efforts. The 2024-2025 publication record shows strong productivity with high-impact papers in Neuro-Oncology, Nature Medicine, and Genome Biology. Elected spokesperson of the DFG Board for Neuroscience (2024) Active participation in EANO guideline development Leadership in multiple international consortia including ICOM Principal investigator for clinical trials including N2M2/NOA-20 umbrella trial Professor Tabatabai mentors a large research team including PhD students, medical doctoral candidates, and postdoctoral researchers. Her laboratory maintains active clinical collaborations across neurosurgery, radiation oncology, and medical oncology departments. She is featured in the 'Key To My Research' podcast discussing tumor intelligence and regularly presents at major neuro-oncology conferences including ASCO, EANO, and SNO.

Steven B. Smithمشاهده پروفایل

استاد

• Political Philosophy
• History of Political Thought
• Ancients vs. Moderns
• +۳ مورد دیگر

Steven B. Smith is the Alfred Cowles Professor of Political Science at Yale University, where he has taught since 1984. His academic career includes leadership roles such as Director of Graduate Studies in Political Science, Director of the Special Program in the Humanities, and Acting Chair of Judaic Studies. Research focuses on the history of political philosophy Special attention to the ancients vs. moderns, religion and politics, and theories of representative government The 14 listed publications span 2014-2025 and include topics in pathology, oncology, and medical diagnostics, though their relevance to Smith's political science expertise remains unclear. His teaching includes the acclaimed course Introduction to Political Philosophy , and he has received awards such as the Lex Hixon '63 Prize for Teaching Excellence (2009). Ralph Waldo Emerson Prize from Phi Beta Kappa Lex Hixon '63 Prize for Teaching Excellence (2009)

Martin A. Kriegelمشاهده پروفایل

استاد

• Host-microbiota interactions in autoimmunity
• Gut commensal translocation mechanisms
• Microbiota-induced immune cell migration
• +۵ مورد دیگر

Univ.-Prof. Dr. med. Martin A. Kriegel serves as full Professor and Department Head of the Department of Translational Rheumatology and Immunology at the Institute of Musculoskeletal Medicine, University of Münster, while maintaining an active laboratory at Yale School of Medicine. He leads the Section for Rheumatology and Clinical Immunology (SRKI) at Medical Clinic D, where his team integrates clinical care with cutting-edge microbiome research. His department operates from Röntgenstraße 21 and Von-Esmarch-Str. 54 in Münster, Germany, with extensive collaborations including the "Cells in Motion" research initiative and the CiM-IMPRS graduate program. Dr. Kriegel's research program focuses on the critical interface between host immunity and microbiota, particularly investigating how gut commensals translocate to host tissues and trigger autoimmune responses. His laboratory pioneered the discovery that specific pathobionts like Enterococcus gallinarum and certain Lactobacillus strains can translocate from the gut to mesenteric lymph nodes, liver, and other sites, driving autoimmune responses through molecular mimicry of human autoantigens. His work has established fundamental mechanisms by which microbiota influence rheumatic diseases, cutaneous autoimmunity, and cancer immunology, with particular emphasis on Ro60 autoantigen mimicry, TLR7-dependent pathways, and diet-microbiome interactions. The laboratory employs advanced techniques including gnotobiotic mouse models, humanized systems, and detailed molecular characterization of host-pathobiont interactions. Analysis of Dr. Kriegel's publication record reveals a consistent trajectory of high-impact research connecting microbiome dynamics to autoimmune pathogenesis. His most recent work (2023-2025) demonstrates increasingly sophisticated understanding of how specific bacterial strains influence disease phenotypes across multiple autoimmune conditions, with notable advances in identifying shared microbiome signatures across lupus and inflammatory bowel disease. The publications show progressive refinement from initial observations of microbial translocation to detailed mechanistic insights into tryptophan catabolism pathways, structural basis of molecular mimicry, and diet-sensitive microbial triggers. Dr. Kriegel's scientific recognition includes US Patent No. 11,058,756 B2 for compositions treating autoimmune diseases by reducing enterococcus, reflecting the translational potential of his research. His laboratory receives substantial funding, most notably a $3 million award from the Lupus Research Alliance for the TransLuMi project investigating gut pathobiont translocation in systemic lupus erythematosus. As an educator and mentor, Dr. Kriegel directs a substantial research team including multiple postdocs (Drs. Marcia Pereira, Nathalie Becker), PhD candidates (Anna Brinkhege, Carina Brune, Helen Fuhrmann), and laboratory specialists. He participates in the CiM-IMPRS graduate program and supervises medical students through the MedK program. His laboratory currently manages multiple significant research projects including: (A) intestinal wall permeability and pathobiont translocation in autoimmunity; (B) diet-environment-microbiome interactions; (C) microbiota disruption of immunological tolerance; and (D) microbiome roles in lymphoma development. The Kriegel laboratory maintains state-of-the-art facilities at both Münster and Yale, with specialized capabilities in gnotobiotic research, microbiome analysis, and immune profiling. His team collaborates with international partners including Dr. Eran Elinav at Weizmann Institute, Dr. Nissan Yissachar at Bar-Ilan University, Prof. George Tsokos at Harvard, and Prof. Ilana Brito at Cornell University. The laboratory's website (https://www.medizin.uni-muenster.de/mikrobiom/startseite/) details ongoing projects and research opportunities.

• Machine Learning
• Biomedical Image Analysis
• Medical Imaging
• +۳ مورد دیگر

Professor Jinman Kim is a Professor in the School of Computer Science at the University of Sydney and Director of the Biomedical Data Analysis and Visualisation (BDAV) Lab. He also serves as Research Director of the Telehealth and Technology Centre at Nepean Hospital. His research focuses on machine learning applications in biomedical image analysis, visualization, and multi-modal data processing. Kim holds a PhD in Computer Science from the University of Sydney (2006) and has held roles including Senior Lecturer (2013), Associate Professor (2016), and Professor (2022). He is an Area Editor for Computer Methods and Programs in Biomedicine and actively contributes to AI-driven healthcare initiatives. His academic journey includes a Marie Curie Fellowship at the University of Geneva (2010) and leadership roles in projects like the ARC Training Centre in Innovative Biomedical Engineering. He co-leads the Digital Health Imaging initiative under the Faculty of Engineering’s Digital Science Initiative. Kim has developed teaching programs such as the Master of Digital Health and Data Science, co-taught with the Faculty of Medicine and Health. Research interests span AI in medical imaging, telehealth systems, and interdisciplinary biomedical engineering. His work includes advancements in PET/CT fusion, tumor segmentation, and medical visual analytics. Kim’s lab explores applications like AI in dental education, cutaneous lymphoma detection, and fair AI models for healthcare. Notable collaborations include the Telehealth Remote Monitoring System for chronic patients and contributions to datasets like the HRDC Challenge for hypertension classification. His labs prioritize translating AI innovations into clinical tools for improved healthcare accessibility and precision.